Semin Respir Crit Care Med 2019; 40(06): 857-868
DOI: 10.1055/s-0039-3400289
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Adult Care in Cystic Fibrosis

J. Stuart Elborn
1   Centre for Experimental Medicine, Queen's University, Belfast, Northern Ireland, United Kingdom
2   National Heart and Lung Institute, Imperial College London, London, United Kingdom
› Author Affiliations
Further Information

Publication History

Publication Date:
30 December 2019 (online)

Abstract

Cystic fibrosis (CF) is now more common in adults than children in countries with well-developed health care systems. The number of adults continues to increase and will further increase if the new cystic fibrosis transmembrane conductance regulator (CFTR) modulators are disease modifying. Most of the complex morbidity and almost all the mortality of CF occur in adults and will increasingly follow this pattern even with new effective modulator therapies. Maintaining good quality of life including social functioning and maximizing survival for adults are the key priorities. This requires a highly knowledgeable and adaptable multidisciplinary team, which, though focused on maintaining lung health, requires an increasing range of other disciplines and specialties to maximize well-being. Changes in health care systems will require current models of care to adapt to provide care for the large number of adult patients. With increasing survival and age, many are likely to have both CF morbidities and additional diseases of aging. New models are needed for health care delivery for this expanding population with complex medical conditions.

 
  • References

  • 1 Elborn JS. Cystic fibrosis. Lancet 2016; 388 (10059): 2519-2531
  • 2 Burgel PR, Bellis G, Olesen HV. , et al; ERS/ECFS Task Force on Provision of Care for Adults with Cystic Fibrosis in Europe. Future trends in cystic fibrosis demography in 34 European countries. Eur Respir J 2015; 46 (01) 133-141
  • 3 Stephenson AL, Sykes J, Stanojevic S. , et al. Survival comparison of patients with cystic fibrosis in Canada and the United States: a population-based cohort study. Ann Intern Med 2017; 166 (08) 537-546
  • 4 Elborn JS, Shale DJ, Britton JR. Cystic fibrosis: current survival and population estimates to the year 2000. Thorax 1991; 46 (12) 881-885
  • 5 Elborn JS, Bell SC, Madge SL. , et al. Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis. Eur Respir J 2016; 47 (02) 420-428
  • 6 Madge S, Bell SC, Burgel PR, De Rijcke K, Blasi F, Elborn JS. ; ERS/ECFS task force: The provision of care for adults with cystic fibrosis in Europe. Limitations to providing adult cystic fibrosis care in Europe: results of a care centre survey. J Cyst Fibros 2017; 16 (01) 85-88
  • 7 Peeters MAC, Sattoe JNT, van Staa A. , et al. Controlled evaluation of a transition clinic for Dutch young people with cystic fibrosis. Pediatr Pulmonol 2019; 54 (11) 1-10
  • 8 Haarbauer-Krupa J, Alexander NM, Mee L. , et al. Readiness for transition and health-care satisfaction in adolescents with complex medical conditions. Child Care Health Dev 2019; 45 (03) 463-471
  • 9 UK CF Registry. https://www.cysticfibrosis.org.uk/the-work-we-do/uk-cf-registry/reporting-and-resources . Accessed October 1, 2019
  • 10 Ronan NJ, Elborn JS, Plant BJ. Current and emerging comorbidities in cystic fibrosis. Presse Med 2017; 46 (6 Pt 2): e125-e138
  • 11 Plant BJ, Goss CH, Plant WD, Bell SC. Management of comorbidities in older patients with cystic fibrosis. Lancet Respir Med 2013; 1 (02) 164-174
  • 12 Mainbourg S, Durieu I, Dehillotte C, Reynaud Q. Extra-respiratory comorbidities and transplantation in the French cystic fibrosis registry. Expert Rev Respir Med 2019; 13 (08) 799-802
  • 13 Elborn JS. CFTR modulators: deciding what is best for individuals in an era of precision medicine. Ann Am Thorac Soc 2018; 15 (03) 298-300
  • 14 Villanueva G, Marceniuk G, Murphy MS, Walshaw M, Cosulich R. ; Guideline Committee. Diagnosis and management of cystic fibrosis: summary of NICE guidance. BMJ 2017; 359: j4574
  • 15 Benden C, Goldfarb SB, Stehlik J. An aging population of patients with cystic fibrosis undergoes lung transplantation: an analysis of the ISHLT Thoracic Transplant Registry. J Heart Lung Transplant 2019; (e-pub ahead of print) DOI: 10.1016/j.healun.2019.06.025.
  • 16 Elborn JS, Gonska T. Using registries for research in CF. How can we be sure about the outputs?. J Cyst Fibros 2019; 18 (03) 309-310
  • 17 Floto RA, Olivier KN, Saiman L. , et al; US Cystic Fibrosis Foundation and European Cystic Fibrosis Society. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax 2016; 71 (Suppl. 01) i1-i22
  • 18 Quittner AL, Abbott J, Georgiopoulos AM. , et al; International Committee on Mental Health; EPOS Trial Study Group. International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety. Thorax 2016; 71 (01) 26-34
  • 19 Smyth AR, Bell SC, Bojcin S. , et al; European Cystic Fibrosis Society. European Cystic Fibrosis Society standards of care: best practice guidelines. J Cyst Fibros 2014; 13 (Suppl. 01) S23-S42
  • 20 Stern M, Bertrand DP, Bignamini E. , et al. European Cystic Fibrosis Society standards of care: quality management in cystic fibrosis. J Cyst Fibros 2014; 13 (Suppl. 01) S43-S59
  • 21 Kerem E, Conway S, Elborn S, Heijerman H. ; Consensus Committee. Standards of care for patients with cystic fibrosis: a European consensus. J Cyst Fibros 2005; 4 (01) 7-26
  • 22 Ramos KJ, Smith PJ, McKone EF. , et al; CF Lung Transplant Referral Guidelines Committee. Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines. J Cyst Fibros 2019; 18 (03) 321-333
  • 23 Conway S, Balfour-Lynn IM, De Rijcke K. , et al. European Cystic Fibrosis Society standards of care: framework for the Cystic Fibrosis Centre. J Cyst Fibros 2014; 13 (Suppl. 01) S3-S22
  • 24 Büssing A, Falkenberg Z, Schoppe C, Recchia DR, Poier D. Work stress associated cool down reactions among nurses and hospital physicians and their relation to burnout symptoms. BMC Health Serv Res 2017; 17 (01) 551
  • 25 Gawande A. Being Mortal: Medicine and What Matters in the End. New York, NY: Henry Holt; 2014
  • 26 Davies J, Sheridan H, Bell N. , et al. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial. Lancet Respir Med 2017; 5 (07) PE26
  • 27 McCormick J, Mehta G, Olesen HV, Viviani L, Macek Jr M, Mehta A. ; European Registry Working Group. Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis. Lancet 2010; 375 (9719): 1007-1013
  • 28 De Boeck K, Fajac I. No easy road to better cystic fibrosis care in Eastern Europe?. J Cyst Fibros 2018; 17 (04) 423-424
  • 29 Sahni S, Talwar A, Khanijo S, Talwar A. Socioeconomic status and its relationship to chronic respiratory disease. Adv Respir Med 2017; 85 (02) 97-108
  • 30 Taylor-Robinson D, Diggle P, Smyth R, Whitehead M. Health trajectories in people with cystic fibrosis in the UK: exploring the effect of social deprivation. In: Burton-Jeangros C, Cullati S, Sacker A, Blane D. , eds. A Life Course Perspective on Health Trajectories and Transitions. Cham: Springer; 2015
  • 31 Oates GR, Schechter MS. Socioeconomic status and health outcomes: cystic fibrosis as a model. Expert Rev Respir Med 2016; 10 (09) 967-977
  • 32 Chevreul K, Michel M, Brigham KB. , et al; BURQOL-RD Research Network. Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe. Eur J Health Econ 2016; 17 (Suppl. 01) 7-18
  • 33 Davies JC, Drevinek P, Elborn JS. , et al; European CF Society (ECFS) Strategic Planning Task Force on ‘Speeding up access to new 4 drugs for CF’. Speeding up access to new drugs for CF: considerations for clinical trial design and delivery. J Cyst Fibros 2019; 18 (05) 677-684
  • 34 MacKenzie T, Gifford AH, Sabadosa KA. , et al. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry. Ann Intern Med 2014; 161 (04) 233-241
  • 35 Keogh RH, Szczesniak R, Taylor-Robinson D, Bilton D. Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: a longitudinal study using UK patient registry data. J Cyst Fibros 2018; 17 (02) 218-227
  • 36 Castellani C, Massie J, Sontag M, Southern KW. Newborn screening for cystic fibrosis. Lancet Respir Med 2016; 4 (08) 653-661
  • 37 Farrell PM, White TB, Derichs N, Castellani C, Rosenstein BJ. Cystic fibrosis diagnostic challenges over 4 decades: historical perspectives and lessons learned. J Pediatr 2017; 181S: S16-S26
  • 38 David J, Chrastina P, Pešková K. , et al. Epidemiology of rare diseases detected by newborn screening in the Czech Republic. Cent Eur J Public Health 2019; 27 (02) 153-159
  • 39 Castellani C, Duff AJA, Bell SC. , et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros 2018; 17 (02) 153-178
  • 40 Frey S, Stargardt T, Schneider U, Schreyögg J. The Economic burden of cystic fibrosis in Germany from a payer perspective. Pharmacoeconomics 2019; 37 (08) 1029-1039
  • 41 Mohindru B, Turner D, Sach T. , et al. Health economic modelling in cystic fibrosis: a systematic review. J Cyst Fibros 2019; 18 (04) 452-460
  • 42 Carson SS, Goss CH, Patel SR. , et al; American Thoracic Society Comparative Effectiveness Research Working Group. An official American Thoracic Society research statement: comparative effectiveness research in pulmonary, critical care, and sleep medicine. Am J Respir Crit Care Med 2013; 188 (10) 1253-1261
  • 43 Chrysochoou EA, Hatziagorou E, Kirvassilis F, Tsanakas J. Telephone monitoring and home visits significantly improved the quality of life, treatment adherence and lung function in children with cystic fibrosis. Acta Paediatr 2017; 106 (11) 1882
  • 44 Lechtzin N, Mayer-Hamblett N, West NE. , et al; eICE Study Team. Home monitoring of patients with cystic fibrosis to identify and treat acute pulmonary exacerbations. eICE Study Results. Am J Respir Crit Care Med 2017; 196 (09) 1144-1151
  • 45 NICE Cystic fibrosis: diagnosis and management. https://www.nice.org.uk/guidance/ng78 . Accessed September 10, 2019
  • 46 Frost F, Dyce P, Ochota A. , et al. Cystic fibrosis-related diabetes: optimizing care with a multidisciplinary approach. Diabetes Metab Syndr Obes 2019; 12: 545-552
  • 47 Debray D, Narkewicz MR, Bodewes FAJA. , et al. Cystic fibrosis-related liver disease: research challenges and future perspectives. J Pediatr Gastroenterol Nutr 2017; 65 (04) 443-448
  • 48 NICE Transition from children's to adults' services for young people using health or social care services. https://www.nice.org.uk/guidance/ng43 . Accessed September 10, 2019
  • 49 Bowmer G, Sowerby C, Duff A. Transition and transfer of young people with cystic fibrosis to adult care. Nurs Child Young People 2018; 30 (05) 34-39
  • 50 Okumura MJ, Kleinhenz ME. Cystic fibrosis transitions of care: lessons learned and future directions for cystic fibrosis. Clin Chest Med 2016; 37 (01) 119-126
  • 51 Regard L, Martin C, Chassagnon G, Burgel PR. Acute and chronic non-pulmonary complications in adults with cystic fibrosis. Expert Rev Respir Med 2019; 13 (01) 23-38
  • 52 Schaffer K. Epidemiology of infection and current guidelines for infection prevention in cystic fibrosis patients. J Hosp Infect 2015; 89 (04) 309-313
  • 53 Saiman L, Siegel J. Cystic Fibrosis Foundation Consensus Conference on Infection Control Participants. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect Control Hosp Epidemiol 2003; 31 (3 Suppl): S1-62
  • 54 Cystic Fibrosis Trust. Consensus documents. https://www.cysticfibrosis.org.uk/the-work-we-do/resources-for-cf-professionals/consensus-documents . Accessed September 10, 2019
  • 55 Somayaji R, Parkins MD, Shah A. , et al; Antimicrobial Resistance in Cystic Fibrosis InternationalWorking Group. Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: a systematic review. J Cyst Fibros 2019; 18 (02) 236-243
  • 56 Flume PA, Waters VJ, Bell SC, Van Devanter DR, Stuart Elborn J. ; Antimicrobial Resistance in Cystic Fibrosis International Working Group. Antimicrobial resistance in cystic fibrosis: does it matter?. J Cyst Fibros 2018; 17 (06) 687-689
  • 57 Abdolrasouli A, Scourfield A, Rhodes J. , et al. High prevalence of triazole resistance in clinical Aspergillus fumigatus isolates in a specialist cardiothoracic centre. Int J Antimicrob Agents 2018; 52 (05) 637-642
  • 58 Chmiel JF, Aksamit TR, Chotirmall SH. , et al. Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections. Ann Am Thorac Soc 2014; 11 (07) 1120-1129
  • 59 Döring G, Flume P, Heijerman H, Elborn JS. ; Consensus Study Group. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 2012; 11 (06) 461-479
  • 60 Flume PA, Mogayzel Jr PJ, Robinson KA. , et al; Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009; 180 (09) 802-808
  • 61 Waters V, Stanojevic S, Atenafu EG. , et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J 2012; 40 (01) 61-66
  • 62 de Boer K, Vandemheen KL, Tullis E. , et al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax 2011; 66 (08) 680-685
  • 63 Elborn JS. Cystic Fibrosis Treatment and Prevention of Pulmonary Exacerbations. In: Burgel PR, Contoli M, López-Campos JL. Acute Exacerbations of Pulmonary Diseases: ERS Monograph. European Respiratory Society; 2017: 167-180
  • 64 Parkins MD, Parkins VM, Rendall JC, Elborn S. Changing epidemiology and clinical issues arising in an ageing cystic fibrosis population. Ther Adv Respir Dis 2011; 5 (02) 105-119
  • 65 Le C, McCrary HC, Chang E. Cystic Fibrosis Sinusitis. Adv Otorhinolaryngol 2016; 79: 29-37
  • 66 Moran F, Bradley JM, Piper AJ. Non-invasive ventilation for cystic fibrosis. Cochrane Database Syst Rev 2017; 2: CD002769
  • 67 Morrell MR, Pilewski JM. Lung transplantation for cystic fibrosis. Clin Chest Med 2016; 37 (01) 127-138
  • 68 Lynch III JP, Sayah DM, Belperio JA, Weigt SS. Lung transplantation for cystic fibrosis: results, indications, complications, and controversies. Semin Respir Crit Care Med 2015; 36 (02) 299-320
  • 69 Hilty MP, Riva T, Cottini SR, Kleinert EM, Maggiorini A, Maggiorini M. Low flow veno-venous extracorporeal CO2 removal for acute hypercapnic respiratory failure. Minerva Anestesiol 2017; 83 (08) 812-823
  • 70 Schellongowski P, Riss K, Staudinger T. , et al. Extracorporeal CO2 removal as bridge to lung transplantation in life-threatening hypercapnia. Transpl Int 2015; 28 (03) 297-304
  • 71 Singh VK, Schwarzenberg SJ. Pancreatic insufficiency in cystic fibrosis. J Cyst Fibros 2017; 16 (Suppl. 02) S70-S78
  • 72 Abraham JM, Taylor CJ. Cystic fibrosis & disorders of the large intestine: DIOS, constipation, and colorectal cancer. J Cyst Fibros 2017; 16 (Suppl. 02) S40-S49
  • 73 Colombo C, Ellemunter H, Houwen R, Munck A, Taylor C, Wilschanski M. ; ECFS. Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients. J Cyst Fibros 2011; 10 (Suppl. 02) S24-S28
  • 74 Gelfond D, Heltshe S, Ma C. , et al. Impact of CFTR modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis and the G551D mutation. Clin Transl Gastroenterol 2017; 8 (03) e81
  • 75 Freeman AJ, Ooi CY. Pancreatitis and pancreatic cystosis in cystic fibrosis. J Cyst Fibros 2017; 16 (Suppl. 02) S79-S86
  • 76 Boudreau V, Reynaud Q, Dubois CL. , et al. Screening for cystic fibrosis-related diabetes: matching pathophysiology and addressing current challenges. Can J Diabetes 2016; 40 (05) 466-470
  • 77 Prentice B, Hameed S, Verge CF, Ooi CY, Jaffe A, Widger J. Diagnosing cystic fibrosis-related diabetes: current methods and challenges. Expert Rev Respir Med 2016; 10 (07) 799-811
  • 78 Moheet A, Moran A. CF-related diabetes: containing the metabolic miscreant of cystic fibrosis. Pediatr Pulmonol 2017; 52 (S48): S37-S43
  • 79 Middleton PG, Wagenaar M, Matson AG. , et al. Australian standards of care for cystic fibrosis-related diabetes. Respirology 2014; 19 (02) 185-192
  • 80 Moran A. Cystic-fibrosis-related diabetes: time for oral drugs?. Lancet Diabetes Endocrinol 2018; 6 (02) 85-87
  • 81 Onady GM, Stolfi A. Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database Syst Rev 2013; (07) CD004730
  • 82 Scheuing N, Badenhoop K, Borkenstein M. , et al; German/Austrian Diabetes Prospective Documentation Initiative. Why is insulin pump treatment rarely used in adolescents and young adults with cystic fibrosis-related diabetes?. Pediatr Diabetes 2015; 16 (01) 10-15
  • 83 Moran A, Brunzell C, Cohen RC. , et al; CFRD Guidelines Committee. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010; 33 (12) 2697-2708
  • 84 Woodruff SA, Sontag MK, Accurso FJ, Sokol RJ, Narkewicz MR. Prevalence of elevated liver enzymes in children with cystic fibrosis diagnosed by newborn screen. J Cyst Fibros 2017; 16 (01) 139-145
  • 85 Kamal N, Surana P, Koh C. Liver disease in patients with cystic fibrosis. Curr Opin Gastroenterol 2018; 34 (03) 146-151
  • 86 Ratchford TL, Teckman JH, Patel DR. Gastrointestinal pathophysiology and nutrition in cystic fibrosis. Expert Rev Gastroenterol Hepatol 2018; 12 (09) 853-862
  • 87 Hollander FM, de Roos NM, Heijerman HGM. The optimal approach to nutrition and cystic fibrosis: latest evidence and recommendations. Curr Opin Pulm Med 2017; 23 (06) 556-561
  • 88 Bell SC, Bowerman AM, Nixon LE, Macdonald IA, Elborn JS, Shale DJ. Metabolic and inflammatory responses to pulmonary exacerbation in adults with cystic fibrosis. Eur J Clin Invest 2000; 30 (06) 553-559
  • 89 Bell SC, Saunders MJ, Elborn JS, Shale DJ. Resting energy expenditure and oxygen cost of breathing in patients with cystic fibrosis. Thorax 1996; 51 (02) 126-131
  • 90 Sullivan JS, Mascarenhas MR. Nutrition: prevention and management of nutritional failure in Cystic Fibrosis. J Cyst Fibros 2017; 16 (Suppl. 02) S87-S93
  • 91 Turck D, Braegger CP, Colombo C. , et al. ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clin Nutr 2016; 35 (03) 557-577
  • 92 Stallings VA, Stark LJ, Robinson KA, Feranchak AP, Quinton H. ; Clinical Practice Guidelines on Growth and Nutrition Subcommittee; Ad Hoc Working Group. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc 2008; 108 (05) 832-839
  • 93 Johnson S, Knox AJ. Arthropathy in cystic fibrosis. Respir Med 1994; 88 (08) 567-570
  • 94 Marquette M, Haworth CS. Bone health and disease in cystic fibrosis. Paediatr Respir Rev 2016; 20 (Suppl): 2-5
  • 95 Jacquot J, Delion M, Gangloff S, Braux J, Velard F. Bone disease in cystic fibrosis: new pathogenic insights opening novel therapies. Osteoporos Int 2016; 27 (04) 1401-1412
  • 96 Tran JR, Chen H, Zheng X, Zheng Y. Lamin in inflammation and aging. Curr Opin Cell Biol 2016; 40: 124-130
  • 97 Yahiaoui Y, Jablonski M, Hubert D. , et al. Renal involvement in cystic fibrosis: diseases spectrum and clinical relevance. Clin J Am Soc Nephrol 2009; 4 (05) 921-928
  • 98 Santoro D, Postorino A, Lucanto C. , et al. Cystic fibrosis: a risk condition for renal disease. J Ren Nutr 2017; 27 (06) 470-473
  • 99 Crawford TC, Magruder JT, Grimm JC. , et al. Impaired renal function should not be a barrier to transplantation in patients with cystic fibrosis. Ann Thorac Surg 2017; 104 (04) 1231-1236
  • 100 Stehling F, Büscher R, Grosse-Onnebrink J, Hoyer PF, Mellies U. Glomerular and tubular renal function after repeated once-daily tobramycin courses in cystic fibrosis patients. Pulm Med 2017; 2017: 2602653
  • 101 Yamada A, Komaki Y, Komaki F, Micic D, Zullow S, Sakuraba A. Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis. Lancet Oncol 2018; 19 (06) 758-767
  • 102 Hadjiliadis D, Khoruts A, Zauber AG, Hempstead SE, Maisonneuve P, Lowenfels AB. ; Cystic Fibrosis Colorectal Cancer Screening Task Force. Cystic fibrosis colorectal cancer screening consensus recommendations. Gastroenterology 2018; 154 (03) 736-745.e14
  • 103 Ooi CY, Durie PR. Cystic fibrosis from the gastroenterologist's perspective. Nat Rev Gastroenterol Hepatol 2016; 13 (03) 175-185
  • 104 Fink AK, Yanik EL, Marshall BC. , et al. Cancer risk among lung transplant recipients with cystic fibrosis. J Cyst Fibros 2017; 16 (01) 91-97
  • 105 Hayes Jr D, Sweet SC, Benden C. , et al. Transplant center volume and outcomes in lung transplantation for cystic fibrosis. Transpl Int 2017; 30 (04) 371-377
  • 106 Dellon EP, Goggin J, Chen E. , et al. Defining palliative care in cystic fibrosis: a Delphi study. J Cyst Fibros 2018; 17 (03) 416-421
  • 107 Friedman D, Linnemann RW, Altstein LL. , et al. The CF-CARES primary palliative care model: a CF-specific structured assessment of symptoms, distress, and coping. J Cyst Fibros 2018; 17 (01) 71-77
  • 108 Linnemann RW, O'Malley PJ, Friedman D. , et al. Development and evaluation of a palliative care curriculum for cystic fibrosis healthcare providers. J Cyst Fibros 2016; 15 (01) 90-95
  • 109 Cystic Fibrosis Family Connection. Advanced CF Lung Disease Guidelines. https://cffamilyconnection.org/input-request-advanced-cf-lung-disease-guidelines/ . Accessed September 10, 2019
  • 110 De Boeck K, Vermeulen F, Dupont L. The diagnosis of cystic fibrosis. Presse Med 2017; 46 (6 Pt 2): e97-e108
  • 111 Nick JA, Nichols DP. Diagnosis of adult patients with cystic fibrosis. Clin Chest Med 2016; 37 (01) 47-57
  • 112 Farrell PM, White TB, Ren CL. , et al. Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation. J Pediatr 2017; 181S: S4-S15 , 15.e1
  • 113 Hill AT, Sullivan AL, Chalmers JD. , et al. British Thoracic Society guideline for bronchiectasis in adults. BMJ Open Respir Res 2018; 5 (01) e000348
  • 114 Polverino E, Goeminne PC, McDonnell MJ. , et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J 2017; 50 (03) 1700629
  • 115 Naehrlich L, Ballmann M, Davies J. , et al; ECFS Diagnostic Network Working Group. Nasal potential difference measurements in diagnosis of cystic fibrosis: an international survey. J Cyst Fibros 2014; 13 (01) 24-28
  • 116 Castellani C, Cuppens H, Macek Jr M. , et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros 2008; 7 (03) 179-196
  • 117 Dekkers JF, Wiegerinck CL, de Jonge HR. , et al. A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat Med 2013; 19 (07) 939-945
  • 118 CFTR2 https://cftr2.org/ . Accessed September 10, 2019
  • 119 Brodlie M, Haq IJ, Roberts K, Elborn JS. Targeted therapies to improve CFTR function in cystic fibrosis. Genome Med 2015; 7: 101
  • 120 Chin M, Aaron SD, Bell SC. The treatment of the pulmonary and extrapulmonary manifestations of cystic fibrosis. Presse Med 2017; 46 (6 Pt 2): e139-e164
  • 121 Nichols DP, Kuk KN, Nick JA. Drug interactions and treatment burden as survival improves. Curr Opin Pulm Med 2015; 21 (06) 617-625
  • 122 Rowbotham NJ, Smith SJ, Elliott ZC. , et al. Adapting the James Lind Alliance priority setting process to better support patient participation: an example from cystic fibrosis. Res Involv Engagem 2019; 5: 24
  • 123 Rowbotham NJ, Smith S, Prayle AP, Robinson KA, Smyth AR. Gaps in the evidence for treatment decisions in cystic fibrosis: a systematic review. Thorax 2019; 74 (03) 229-236
  • 124 Drabble SJ, O'Cathain A, Arden MA, Hutchings M, Beever D, Wildman M. When is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qual Health Res 2019; (e-pub ahead of print) DOI: 10.1177/1049732319856580.
  • 125 Arden MA, Drabble S, O'Cathain A, Hutchings M, Wildman M. Adherence to medication in adults with cystic fibrosis: an investigation using objective adherence data and the Theoretical Domains Framework. Br J Health Psychol 2019; 24 (02) 357-380
  • 126 Hind D, Drabble SJ, Arden MA. , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulm Med 2019; 19 (01) 77
  • 127 Gao J, Arden M, Hoo ZH, Wildman M. Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Serv Res 2019; 19 (01) 420
  • 128 Mooney K, Ryan C, Downey DG. Pharmacists' perspectives on monitoring adherence to treatment in cystic fibrosis. Int J Clin Pharm 2016; 38 (02) 296-302
  • 129 Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: a systematic review of cost of illness evidence. Health Policy 2015; 119 (07) 964-979
  • 130 Ahmad A, Ahmed A, Patrizio P. Cystic fibrosis and fertility. Curr Opin Obstet Gynecol 2013; 25 (03) 167-172
  • 131 Tournier A, Murris M, Prevotat A, Fanton A, Bettiol C, Parinaud J. Fertility of women with cystic fibrosis: a French survey. Reprod Biomed Online 2019; 39 (03) 492-495
  • 132 Edenborough FP, Borgo G, Knoop C. , et al; European Cystic Fibrosis Society. Guidelines for the management of pregnancy in women with cystic fibrosis. J Cyst Fibros 2008; 7 (Suppl. 01) S2-S32
  • 133 Shteinberg M, Lulu AB, Downey DG. , et al. Failure to conceive in women with CF is associated with pancreatic insufficiency and advancing age. J Cyst Fibros 2019; 18 (04) 525-529
  • 134 Traxler SA, Chavez V, Hadjiliadis D, Shea JA, Mollen C, Schreiber CA. Fertility considerations and attitudes about family planning among women with cystic fibrosis. Contraception 2019; 100 (03) 228-233
  • 135 Hailey CE, Tan JW, Dellon EP, Park EM. Pursuing parenthood with cystic fibrosis: reproductive health and parenting concerns in individuals with cystic fibrosis. Pediatr Pulmonol 2019; 54 (08) 1225-1233
  • 136 Bourke SJ, Anderson A, Briggs J. , et al. Current status of fertility and family formation in men with cystic fibrosis. Hum Fertil (Camb) 2019; ( e-pub ahead of print) DOI: 10.1080/14647273.2019.1656824.
  • 137 Heltshe SL, Godfrey EM, Josephy T, Aitken ML, Taylor-Cousar JL. Pregnancy among cystic fibrosis women in the era of CFTR modulators. J Cyst Fibros 2017; 16 (06) 687-694
  • 138 Smith BA, Georgiopoulos AM, Quittner AL. Maintaining mental health and function for the long run in cystic fibrosis. Pediatr Pulmonol 2016; 51 (S44): S71-S78
  • 139 Verkleij M, de Winter D, Hurley MA, Abbott J. Implementing the International Committee on Mental Health in Cystic Fibrosis (ICMH) guidelines: screening accuracy and referral-treatment pathways. J Cyst Fibros 2018; 17 (06) 821-827
  • 140 Abbott J, Elborn JS, Georgiopoulos AM. , et al. Cystic Fibrosis Foundation and European Cystic Fibrosis Society Survey of cystic fibrosis mental health care delivery. J Cyst Fibros 2015; 14 (04) 533-539
  • 141 Quittner AL, Saez-Flores E, Barton JD. The psychological burden of cystic fibrosis. Curr Opin Pulm Med 2016; 22 (02) 187-191
  • 142 Platten MJ, Newman E, Quayle E. Self-esteem and its relationship to mental health and quality of life in adults with cystic fibrosis. J Clin Psychol Med Settings 2013; 20 (03) 392-399
  • 143 Knudsen KB, Pressler T, Mortensen LH. , et al. Associations between adherence, depressive symptoms and health-related quality of life in young adults with cystic fibrosis. Springerplus 2016; 5 (01) 1216
  • 144 Oliver KN, Free ML, Bok C, McCoy KS, Lemanek KL, Emery CF. Stigma and optimism in adolescents and young adults with cystic fibrosis. J Cyst Fibros 2014; 13 (06) 737-744
  • 145 Taylor-Robinson DC, Smyth RL, Diggle PJ, Whitehead M. The effect of social deprivation on clinical outcomes and the use of treatments in the UK cystic fibrosis population: a longitudinal study. Lancet Respir Med 2013; 1 (02) 121-128
  • 146 Blasi F, Elborn JS, Palange P. Adults with cystic fibrosis and pulmonologists: new training needed to recruit future specialists. Eur Respir J 2019; 53 (01) 1802209